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Essentials
• We report thrombin generation in a woman with factor V Leiden taking combined oral contraceptives.
• The thrombin generation profile improved greatly after discontinuation of combined oral contraceptives.
• Thrombin generation reflects the multiplicative effect of combined oral contraceptives and factor V Leiden mutation.
• Thrombin generation may be a promising tool to identify women at high thrombotic risk taking combined oral contraceptives.
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Abstract
Combined oral contraceptives and factor V Leiden mutation are multiplicative risk fac-
tors for venous thromboembolism. However, it remains unknown whether this multipli-
cative effect is reflected in thrombin generation assays. We report here the evolution 
of the thrombin generation profile while taking combined oral contraceptives and after 
their discontinuation in a woman with heterozygous factor V Leiden mutation. The 
proband exhibited a distinctly prothrombotic thrombin generation profile including 
markedly decreased thrombomodulin (TM) sensitivity, compared to the control popula-
tion. This profile possibly reflected a high thrombotic risk. After discontinuation of com-
bined oral contraceptives, thrombin generation and TM sensitivity improved greatly, 
leaving only a slightly prothrombotic profile. Therefore, the multiplied thrombotic risk 
occurring with simultaneous combined oral contraceptives and factor V Leiden muta-
tion is reflected by a thrombin generation assay performed without and with TM. This 
could be a promising tool to identify women taking combined oral contraceptives at high 
risk for venous thromboembolism. Further studies are needed to verify this hypothesis.
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1  | INTRODUCTION
Women taking combined oral contraceptives are at increased throm-
botic risk.1,2 This is due to increased levels of fibrinogen; coagulation 
factors II, VII, VIII, and X; and decreased levels of antithrombin and 
protein S.3 The increased levels of factor VIII and decreased levels of 
protein S lead to an acquired protein C resistance.4,5 Some genetic 
polymorphisms add to the thrombotic risk. Factor V Leiden mutation 
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is the most frequent genetic thrombotic risk factor in Caucasians, 
particularly in Europe.6 It consists of a single point mutation in the 
factor V gene (guanine to adenine in position 1691), leading to a re-
sistance to activated protein C and thus to an increased thrombotic 
risk.6 The simultaneous presence of a combined oral contraceptive 
and factor V Leiden mutation has a multiplicative rather than just an 
additive prothrombotic effect in clinical studies.7 However, it remains 
broadly unknown whether this may be visualized by in vitro thrombin 
generation. We report here the evolution of thrombin generation pro-
file with and without combined oral contraception in a 30-year-old 
woman carrying a heterozygous factor V Leiden mutation.
2  | CASE REPORT
A healthy 30-year-old woman was recruited as proband for the 
pilot phase of the validation of a new fully automated, standardized, 
and normalized thrombin generation assay, ST Genesia Thrombin 
Generation System (Stago, Asnière-sur-Seine, France) and reagents 
ThromboScreen (Stago). In this assay, thrombin generation is meas-
ured in the absence and in the presence of thrombomodulin (TM) 
as a protein C/S system activator. Different parameters were meas-
ured, which are listed in the legend of Figure 1 and in Table S1.
The in vitro thrombin generation profile of the woman (Figure 1 
and Table S1) was strongly increased in comparison to the rest of 
the control population (healthy subjects without any medication 
including combined oral contraception, a personal or family his-
tory of thrombohemorrhagic events, or a known pregnancy). In the 
absence of TM, the velocity index and the peak height of the pro-
band were much higher than in the control population. However, 
she exhibited an endogenous thrombin potential (ETP) within 
normal range. In the presence of TM, the velocity index was even 
higher and the peak height was only slightly decreased compared 
to the values measured in the absence of TM. Again, these 2 pa-
rameters were much higher than in the control population. The 
ratio of peak height with and without TM was higher than in the 
control population as well. Of note, the ETP was still within nor-
mal ranges, but its TM-mediated inhibition was much lower than 
observed in the rest of the control population, indicating a protein 
C resistance (Table S1). Taken together, the proband exhibited a 
distinctly increased thrombin generation profile with decreased 
TM-mediated inhibition, which may represent a severe prothrom-
botic state (see Discussion).
To investigate this incidentally diagnosed laboratory pro-
thrombotic profile, history was recorded. The woman had a fully 
negative personal and familial medical history for venous throm-
boembolism or other thrombotic events. She had 2 pregnancies 
without complications and and had given birth to 2 healthy chil-
dren. She was not pregnant, not breastfeeding, and was in good 
general condition at the time of blood collection. She was under 
no medical treatment except a combined oral contraceptive with 
cyproteron (2 mg) and ethinylestradiol (35 µg). She had been tak-
ing combined oral contraceptives for 8 years, from 18 to 26 years 
of age, and again for the past 18 months. She reported no other 
risk factors for venous thromboembolism.
Because of the severely increased thrombin generation, fur-
ther laboratory analyses were performed. She was negative for 
antiphospholipid antibodies. Antithrombin activity, protein C ac-
tivity, and free protein S antigen were within normal ranges: 128%, 
135%, and 60%, respectively. No prothrombin gene mutation was 
found. However, a heterozygous factor V Leiden mutation was 
revealed.
On the basis of history and laboratory analyses, we interpreted 
the severely increased thrombin generation profile in the frame of 
the association of combined oral contraceptive and factor V Leiden 
mutation.
After discussing the thrombotic risk linked to the combination of 
combined oral contraceptives and factor V Leiden1,2,7 as well as the 
laboratory thrombin generation profile, which potentially reflected 
a prothrombotic state, the woman decided to discontinue the com-
bined oral contraceptive. Thrombin generation was performed again 
8 months after discontinuation of the combined oral contraceptive 
(Figure 1 and Table S1). Velocity index and peak height with and 
without TM as well as the ratio of peak height with and without 
TM decreased and were now within reference ranges. Of note, TM-
mediated inhibition of the ETP had markedly increased and resulted 
within the lower limit of the reference range.
In summary, the proband exhibited a severe prothrombotic labo-
ratory profile due to both combined oral contraceptive and factor V 
Leiden mutation. After discontinuation of the combined oral contra-
ceptive, the prothrombotic profile improved significantly.
F I G U R E  1   Thrombin generation profiles without (continuous 
lines) and with (interrupted lines) thrombomodulin (TM) before 
(black lines) and after discontinuation (gray lines) of combined oral 
contraceptive (COC) in the reported woman. Different parameters 
are measured by the assay: time until thrombin generation (lag 
time), maximal concentration of thrombin (peak height), thrombin 
generation velocity (velocity index), endogenous thrombin potential 
(ETP; area under the curve of thrombin generation, representing 
the total amount of thrombin generated) and the TM-mediated 
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3  | DISCUSSION
Combined oral contraceptives and factor V Leiden mutation are 
multiplicative thrombotic risk factors.7 The various combined 
oral contraceptives confer a different thrombotic risk depend-
ing on their progestin content.8,9 We report here the throm-
bin generation profile of a woman with heterozygous factor V 
Leiden mutation with and without combined oral contraception 
(cyproteron and ethinylestradiol). The contraception with cypro-
teron and ethinylestradiol is known to carry a high risk of venous 
thromboembolism.2,9
In the proband, thrombin generation was strongly increased 
while taking a combined oral contraceptive compared to the 
profile observed after its discontinuation, suggesting a pos-
sibly severe prothrombotic state. The major prothrombotic al-
terations under combined oral contraception were an increase 
of velocity index and peak height as well as a decrease of TM-
mediated ETP inhibition. Of note, ETP was within normal limits 
both under combined oral contraception and after its discontin-
uation. These analyses are in line with previous studies investi-
gating thrombin generation and activated protein C resistance 
in women taking combined oral contraceptives. These studies 
reported increased ETP,10,11 decreased sensitivity to activated 
protein C12,13 (reflected here in the decreased TM-mediated ETP 
inhibition), and increased peak height.12 Interestingly, when the 
proband was taking a combined oral contraceptive, the velocity 
index increased after addition of TM, while after discontinuation 
of the combined oral contraceptive, the velocity index tended to 
decrease. This is possibly due to the decreased protein S induced 
by combined oral contraception.3 Indeed, Tripodi et al.14 also 
observed an increasing velocity index after addition of TM in 
patients with protein S deficiency. Based on the extent of the al-
terations observed in the proband, the thrombin generation pro-
file generated by the ST Genesia Thrombin Generation System 
appears to detect the multiplicative effect of the coexistence of 
these 2 risk factors.
Of note, although the ETP is the thrombin generation pa-
rameter most frequently analyzed and reported, velocity index 
and peak height are probably more sensitive biomarkers of hy-
percoagulability than ETP itself in the presence of both com-
bined oral contraceptives and factor V Leiden mutation (Table 
S1). A similar observation has been already made by our group 
and others in other populations.15‒17 It is therefore important to 
analyze the whole thrombin generation profile and not to focus 
only on ETP.
What if the woman had not participated in the study? Would 
she have suffered a thromboembolic event later? The fact that she 
had a fully negative personal and family history of venous throm-
boembolism questions the predictive value of the observed severe 
laboratory prothrombotic profile for the occurrence of venous 
thromboembolism in women taking combined oral contraceptives. 
Moreover, some data indicate that the risk of venous thrombo-
embolism in women with factor V Leiden mutation and combined 
oral contraceptives is far lower than the risk observed during preg-
nancy and postpartum.18 Nevertheless, the woman, a physician, 
after considering the pros and cons, decided to discontinue the 
combined oral contraceptive. Based on the thrombin generation 
profile and its evolution after discontinuation, this decision seems 
to be rational and congruent with an increasing body of evidence 
for the role of global coagulation assays in identifying a hyperco-
agulable state and possibly predicting thrombotic risk.19 Further 
prospective studies investigating thrombin generation and risk of 
venous thromboembolism should be performed to assess whether 
thrombin generation can identify women taking combined oral 
contraceptives at high thrombotic risk, who would benefit from an 
alternative contraception. This could improve the safety of com-
bined oral contraceptive users.
Testing for factor V Leiden in her young children was not advised 
because of the absence of immediate consequences. However, no 
clear evidence-based recommendation exists yet to clarify whether 
the woman’s daughter should be tested in the future in case of 
combined oral contraceptive prescription or in case of desire for 
pregnancy.20
Of note, the major limitation of this case report is that blood 
collection was not repeated while the proband was taking a com-
bined oral contraceptive to assert the reproducibility of the mea-
sure. However, the biological reproducibility of the assay as well 
as the analytical reproducibility of ST Genesia in our laboratory 
is very good (see Table S3), the thrombin generation results were 
coherent with the presence of a combined oral contraceptive and 
factor V Leiden mutation, and no potential influencing factor (par-
ticularly no other medication and no recent infection) could be 
identified. Therefore, we believe that the data presented here are 
reliable.
The novelty of our case report is the observation that thrombin 
generation studies performed with and without TM appear to iden-
tify the prothrombotic profile known to be induced by the presence 
of combined oral contraceptives and heterozygous factor V Leiden. 
However, to assess its clinical significance, this observation needs to 
be confirmed in additional subjects with these risk factors in various 
combinations and different outcomes.
In conclusion, we reported here a severely increased thrombin 
generation profile in a woman with heterozygous factor V Leiden 
mutation while taking a combined oral contraceptive and a marked 
improvement of the prothrombotic laboratory profile after its dis-
continuation. Thrombin generation could be a promising tool to 
identify women taking combined oral contraceptives possibly at high 
risk for venous thromboembolism. Further studies are needed to in-
vestigate this hypothesis.
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